ES2350575T3 - Desacoplamiento de propagación del adn y expresión de proteína para la expresión en fagos. - Google Patents
Desacoplamiento de propagación del adn y expresión de proteína para la expresión en fagos. Download PDFInfo
- Publication number
- ES2350575T3 ES2350575T3 ES03784882T ES03784882T ES2350575T3 ES 2350575 T3 ES2350575 T3 ES 2350575T3 ES 03784882 T ES03784882 T ES 03784882T ES 03784882 T ES03784882 T ES 03784882T ES 2350575 T3 ES2350575 T3 ES 2350575T3
- Authority
- ES
- Spain
- Prior art keywords
- phage
- expression
- polypeptide
- nucleic acid
- heterologous polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 117
- 108090000623 proteins and genes Proteins 0.000 title claims description 49
- 102000004169 proteins and genes Human genes 0.000 title claims description 29
- 230000003247 decreasing effect Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 139
- 229920001184 polypeptide Polymers 0.000 claims abstract description 138
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 138
- 230000001105 regulatory effect Effects 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 21
- 150000007523 nucleic acids Chemical class 0.000 claims description 45
- 108010052285 Membrane Proteins Proteins 0.000 claims description 42
- 239000013598 vector Substances 0.000 claims description 40
- 108020005038 Terminator Codon Proteins 0.000 claims description 30
- 108091060545 Nonsense suppressor Proteins 0.000 claims description 29
- 239000002245 particle Substances 0.000 claims description 27
- 108020004707 nucleic acids Proteins 0.000 claims description 20
- 102000039446 nucleic acids Human genes 0.000 claims description 20
- 230000001939 inductive effect Effects 0.000 claims description 19
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- 238000003776 cleavage reaction Methods 0.000 claims description 11
- 230000007017 scission Effects 0.000 claims description 11
- 238000012360 testing method Methods 0.000 claims description 11
- 239000011248 coating agent Substances 0.000 claims description 10
- 238000000576 coating method Methods 0.000 claims description 10
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 9
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 9
- 230000003993 interaction Effects 0.000 claims description 9
- 241000701867 Enterobacteria phage T7 Species 0.000 claims description 7
- 230000001143 conditioned effect Effects 0.000 claims description 7
- 230000002255 enzymatic effect Effects 0.000 claims description 7
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 230000003321 amplification Effects 0.000 claims description 5
- 238000002955 isolation Methods 0.000 claims description 5
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 5
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 238000010367 cloning Methods 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 239000004365 Protease Substances 0.000 claims description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 229960005091 chloramphenicol Drugs 0.000 claims description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 238000003780 insertion Methods 0.000 claims description 3
- 230000037431 insertion Effects 0.000 claims description 3
- 101100002068 Bacillus subtilis (strain 168) araR gene Proteins 0.000 claims description 2
- 108700005075 Regulator Genes Proteins 0.000 claims description 2
- 101150044616 araC gene Proteins 0.000 claims description 2
- 102400000368 Surface protein Human genes 0.000 claims 2
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 238000005530 etching Methods 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 238000002823 phage display Methods 0.000 abstract description 19
- 230000004927 fusion Effects 0.000 abstract description 16
- 101710132601 Capsid protein Proteins 0.000 abstract description 5
- 101710094648 Coat protein Proteins 0.000 abstract description 5
- 101710125418 Major capsid protein Proteins 0.000 abstract description 5
- 101710141454 Nucleoprotein Proteins 0.000 abstract description 5
- 101710083689 Probable capsid protein Proteins 0.000 abstract description 5
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 66
- 102000018697 Membrane Proteins Human genes 0.000 description 40
- 235000018102 proteins Nutrition 0.000 description 23
- 102000037865 fusion proteins Human genes 0.000 description 20
- 108020001507 fusion proteins Proteins 0.000 description 20
- 239000002299 complementary DNA Substances 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 9
- 230000006698 induction Effects 0.000 description 8
- 108020004635 Complementary DNA Proteins 0.000 description 7
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 241001515965 unidentified phage Species 0.000 description 6
- 108700010839 phage proteins Proteins 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 4
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 230000000644 propagated effect Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 108090000565 Capsid Proteins Proteins 0.000 description 3
- 102100023321 Ceruloplasmin Human genes 0.000 description 3
- 241000724791 Filamentous phage Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 3
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108090000787 Subtilisin Proteins 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 102100032534 Adenosine kinase Human genes 0.000 description 1
- 108020000543 Adenylate kinase Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000001267 GSK3 Human genes 0.000 description 1
- -1 Genenase I Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000057621 Glycerol kinases Human genes 0.000 description 1
- 108700016170 Glycerol kinases Proteins 0.000 description 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108700027654 Mitogen-Activated Protein Kinase 10 Proteins 0.000 description 1
- 102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102220478107 Myc box-dependent-interacting protein 1_H64A_mutation Human genes 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010076818 TEV protease Proteins 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036438 mutation frequency Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US214654 | 2002-08-07 | ||
| US10/214,654 US7112435B1 (en) | 2002-08-07 | 2002-08-07 | Uncoupling of DNA insert propagation and expression of protein for phage display |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2350575T3 true ES2350575T3 (es) | 2011-01-25 |
Family
ID=31714248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03784882T Expired - Lifetime ES2350575T3 (es) | 2002-08-07 | 2003-08-01 | Desacoplamiento de propagación del adn y expresión de proteína para la expresión en fagos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7112435B1 (enExample) |
| EP (1) | EP1543160B1 (enExample) |
| JP (2) | JP4870351B2 (enExample) |
| AT (1) | ATE483810T1 (enExample) |
| AU (1) | AU2003257132B2 (enExample) |
| CA (1) | CA2493716A1 (enExample) |
| DE (1) | DE60334466D1 (enExample) |
| DK (1) | DK1543160T3 (enExample) |
| ES (1) | ES2350575T3 (enExample) |
| WO (1) | WO2004015142A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7897381B2 (en) | 2002-08-07 | 2011-03-01 | Ambit Biosciences Corporation | Uncoupling of DNA insert propagation and expression of protein for phage display |
| US7833741B2 (en) * | 2002-08-07 | 2010-11-16 | Ambit Biosciences Corporation | Uncoupling of DNA insert propagation and expression of protein for phage display |
| CA2576195A1 (en) * | 2004-08-05 | 2006-02-16 | Biosite Incorporated | Compositions and methods for phage display of polypeptides |
| GB2428293A (en) * | 2005-07-13 | 2007-01-24 | Domantis Ltd | Phage display libraries |
| MY159327A (en) | 2009-02-27 | 2016-12-25 | Ambit Biosciences Corp | Jak kinase modulating quinazoline derivatives and methods of use thereof |
| MX2012001974A (es) | 2009-08-19 | 2012-04-11 | Ambit Biosciences Corp | Compuestos de biarilo y metodos de uso de los mismos. |
| WO2011056764A1 (en) | 2009-11-05 | 2011-05-12 | Ambit Biosciences Corp. | Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles |
| US9296722B2 (en) | 2010-05-27 | 2016-03-29 | Ambit Biosciences Corporation | Azolyl urea compounds and methods of use thereof |
| WO2011150201A2 (en) | 2010-05-27 | 2011-12-01 | Ambit Biosciences Corporation | Azolyl amide compounds and methods of use thereof |
| EP2611793A1 (en) | 2010-09-01 | 2013-07-10 | Ambit Biosciences Corporation | 2-cycloquinazoline derivatives and methods of use thereof |
| EP2663553B1 (en) | 2010-09-01 | 2015-08-26 | Ambit Biosciences Corporation | Quinoline and isoquinoline derivatives for use as jak modulators |
| WO2012030948A1 (en) | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | Quinazoline compounds and methods of use thereof |
| EP2611448A1 (en) | 2010-09-01 | 2013-07-10 | Ambit Biosciences Corporation | 7-cyclylquinazoline derivatives and methods of use thereof |
| AU2011296078B2 (en) | 2010-09-01 | 2015-06-18 | Ambit Biosciences Corporation | An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof |
| EP2611812A1 (en) | 2010-09-01 | 2013-07-10 | Ambit Biosciences Corporation | Thienopyridine and thienopyrimidine compounds and methods of use thereof |
| WO2012030924A1 (en) | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | Azolopyridine and azolopyrimidine compounds and methods of use thereof |
| US20130225614A1 (en) | 2010-09-01 | 2013-08-29 | Ambit Biosciences Corporation | 4-azolylaminoquinazoline derivatives and methods of use thereof |
| AU2012322095B2 (en) | 2011-10-14 | 2017-06-29 | Ambit Biosciences Corporation | Heterocyclic compounds and use thereof as modulators of type III receptor tyrosine kinases |
| US10829484B2 (en) | 2015-07-28 | 2020-11-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2024020328A1 (en) | 2022-07-16 | 2024-01-25 | Eurofins Discoverx Corporation | Binding assays using phage display technology and kits thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5693489A (en) | 1984-03-30 | 1997-12-02 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5498538A (en) | 1990-02-15 | 1996-03-12 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5770356A (en) * | 1992-09-04 | 1998-06-23 | The Scripps Research Institute | Phagemids coexpressing a surface receptor and a surface heterologous protein |
| ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| US5766905A (en) | 1996-06-14 | 1998-06-16 | Associated Universities Inc. | Cytoplasmic bacteriophage display system |
| US20030124555A1 (en) * | 2001-05-21 | 2003-07-03 | Invitrogen Corporation | Compositions and methods for use in isolation of nucleic acid molecules |
| US6541011B2 (en) | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
| JP2002522029A (ja) * | 1998-07-27 | 2002-07-23 | ジェネンテック・インコーポレーテッド | コートタンパク質の改変によるファージ提示における改良した形質転換効率 |
| CA2383186A1 (en) | 1999-09-03 | 2001-03-15 | Yale University | Method to identify gene function using small molecule probes |
| US7060506B2 (en) | 2000-01-31 | 2006-06-13 | Cyclacel, Ltd. | Compositions and methods for monitoring the modification of modification dependent binding partner polypeptides |
| WO2002085923A2 (en) | 2001-04-19 | 2002-10-31 | The Scripps Research Institute | In vivo incorporation of unnatural amino acids |
| US20030186221A1 (en) | 2002-04-02 | 2003-10-02 | Lockhart David J. | Phage display affinity filter and forward screen |
-
2002
- 2002-08-07 US US10/214,654 patent/US7112435B1/en not_active Expired - Lifetime
-
2003
- 2003-08-01 DE DE60334466T patent/DE60334466D1/de not_active Expired - Lifetime
- 2003-08-01 CA CA002493716A patent/CA2493716A1/en not_active Abandoned
- 2003-08-01 ES ES03784882T patent/ES2350575T3/es not_active Expired - Lifetime
- 2003-08-01 EP EP03784882A patent/EP1543160B1/en not_active Expired - Lifetime
- 2003-08-01 JP JP2004527717A patent/JP4870351B2/ja not_active Expired - Lifetime
- 2003-08-01 AU AU2003257132A patent/AU2003257132B2/en not_active Expired
- 2003-08-01 DK DK03784882.7T patent/DK1543160T3/da active
- 2003-08-01 WO PCT/US2003/024221 patent/WO2004015142A1/en not_active Ceased
- 2003-08-01 AT AT03784882T patent/ATE483810T1/de not_active IP Right Cessation
-
2011
- 2011-09-27 JP JP2011210341A patent/JP5389882B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005534333A (ja) | 2005-11-17 |
| CA2493716A1 (en) | 2004-02-19 |
| EP1543160A4 (en) | 2007-03-21 |
| JP4870351B2 (ja) | 2012-02-08 |
| JP2012050444A (ja) | 2012-03-15 |
| EP1543160A1 (en) | 2005-06-22 |
| JP5389882B2 (ja) | 2014-01-15 |
| WO2004015142A1 (en) | 2004-02-19 |
| DK1543160T3 (da) | 2011-01-17 |
| DE60334466D1 (de) | 2010-11-18 |
| AU2003257132A1 (en) | 2004-02-25 |
| AU2003257132B2 (en) | 2011-12-15 |
| US7112435B1 (en) | 2006-09-26 |
| EP1543160B1 (en) | 2010-10-06 |
| ATE483810T1 (de) | 2010-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2350575T3 (es) | Desacoplamiento de propagación del adn y expresión de proteína para la expresión en fagos. | |
| JP7133671B2 (ja) | インビトロウイルスゲノム工学のための組成物及びその方法 | |
| CN110352241A (zh) | 热稳定的Cas9核酸酶 | |
| AU2016308591B2 (en) | Delivery vehicle | |
| CN111465689B (zh) | Cas9变体和使用方法 | |
| KR102876612B1 (ko) | 하나 이상의 비-고유 꼬리 섬유를 가지는 비-복제성 형질도입 입자 및 형질도입 입자-기반 리포터 시스템 | |
| JP5637846B2 (ja) | レシピエント宿主細胞におけるゲノム組込み方法 | |
| CN114945665A (zh) | 用于增强地衣芽孢杆菌中蛋白产生的组合物和方法 | |
| JP2000300254A (ja) | 寄生体由来抵抗性 | |
| Bari et al. | CRISPR–Cas10 assisted editing of virulent staphylococcal phages | |
| CN108165551B (zh) | 一种改进的启动子及其组成的t载体和应用 | |
| EP2084282A2 (en) | Uncoupling of dna insert propagation and expression of protein for phage display | |
| US7897381B2 (en) | Uncoupling of DNA insert propagation and expression of protein for phage display | |
| CN107805634A (zh) | 用于序列操纵的Argonaute‑核酸序列组分系统、方法以及组合物 | |
| Yao et al. | A highly efficient method for the generation of a recombinant Bombyx mori nuclear‐polyhedrosis‐virus Bacmid and large‐scale expression of foreign proteins in silkworm (B. mori) larvae | |
| Loganathan et al. | Genome editing for phage design and uses for therapeutic applications | |
| EP3847252A1 (en) | The gene therapy dna vector gdtt1.8nas12 and the method for obtaining thereof | |
| Chase | DEVELOPMENT OF A GENETIC SYSTEM FOR THE HOST OF STIV3, SULFOLOBUS ACIDOCALDARIUS | |
| Rubert | Towards the design and construction of self-replicating RNA nanostructures | |
| JP5131828B2 (ja) | 新規ブレオマイシン耐性遺伝子 | |
| JP2025508778A (ja) | 生物学的にスケーラブルなナノロッドの生成 | |
| Kunapuli | Analysis of the Clear Plaque Phenotype of the Bacteriophage HK75 | |
| Verma et al. | Genetic Engineering | |
| Tank | Production of Recombinant Molecules | |
| Dove | Quenching biosensor. |